CRISPR/Cas9 technology introduced a TT to GC mutation in exon 17 resulting in a phenylalanine to alanine substitution at amino acid 2872 (F2872A). This mutation is within the Rhot (Miro)-binding region and is predicted to abolish Rhot-binding. (J:273098)